Logo Image
News
Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Watch
Expert ConversationsShows & PodcastsNews & Analysis
Conferences
Publications
All JournalsEditorial BoardFor AuthorsYear in Review
More
Events
Frontline ForumSatellite Sessions
CME/CE
Resources
Awareness MonthThe Bispecifics NetworkNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career Center

Subscribe

  • News
  • Watch
  • Conferences
  • Publications
  • Events
  • CME/CE
  • Resources
  • Career Center
  • Subscribe
  • Adverse Effects
  • Artificial Intelligence
  • Brain Cancer
  • Breast Cancer
    • HER2-Positive Breast Cancer
    • Triple-Negative Breast Cancer
  • Gastrointestinal Cancer
    • Colorectal Cancer
    • Esophageal Cancer
    • Pancreatic Cancer
    • Gastric Cancer
    • Liver Cancer
  • Genitourinary Cancers
    • Kidney Cancer
    • Bladder Cancer
    • Prostate Cancer
  • Gynecologic Cancers
    • Endometrial Cancer
    • Ovarian Cancer
    • Cervical Cancer
  • Head & Neck Cancer
  • Hematologic Oncology
    • Multiple Myeloma
    • Myelodysplastic Syndromes
    • Myeloproliferative Neoplasms
  • Infection
    • Vaccines
  • Leukemia
  • Lung Cancer
    • Small Cell Lung Cancer (SCLC)
    • Non-Small Cell Lung Cancer (NSCLC)
  • Lymphoma
  • Neuroendocrine Tumors
  • Oncology
  • Pediatric Cancers
  • Psycho-Oncology
  • Radiation Oncology
  • Sarcoma
  • Screening
  • Skin Cancer & Melanoma
  • Surgery
  • Thyroid Cancer
Spotlight -
Psycho-Oncology|
Artificial Intelligence|
Career Center|
Radiation Oncology|
Surgery
Advertisement

Grzegorz Panek, MD, PhD

Advertisement

Articles by Grzegorz Panek, MD, PhD

The Usefulness of Indocyanine Green in Cytoreductive Ovarian Cancer Surgery: © Kathy Mathews - stock.adobe.com

The Usefulness of Indocyanine Green in Cytoreductive Ovarian Cancer Surgery

ByMichał Kostrzanowski, MD,Michał Ciebiera, MD, PhD,Grzegorz Ziółkowski, MD,Agata Mandes, MD,Grzegorz Panek, MD, PhD,Filip Dąbrowski, MD, PhD
October 20th 2026

Indocyanine green may be highly sensitive in the identification of ovarian cancer metastases, though with low specificity.

Synchronous Endometrial and Ovarian Cancers: A Case Study and Literature Review

ByMichał Kostrzanowski, MD,Adam Górski, MD,Grzegorz Panek, MD, PhD,Grzegorz Ziółkowski, MD,Agata Mandes, MD,Filip Dąbrowski, MD, PhD
April 23rd 2026
Advertisement

Latest Updated Articles

  • Synchronous Endometrial and Ovarian Cancers: A Case Study and Literature Review
    Synchronous Endometrial and Ovarian Cancers: A Case Study and Literature Review

    April 23rd 2026



Advertisement
Advertisement

Trending on CancerNetwork

1

Intismeran Plus Pembrolizumab Reduces Recurrence Risk in Resected Melanoma

2

What Pope Leo XIV’s Lung Cancer Diagnosis Could Mean for Stigma & Nihilism

3

FDA Approves Pembrolizumab in Metastatic TMB-H Solid Tumors

4

Zipalertinib May Introduce Another Option to EGFR Exon 20+ NSCLC

5

Perioperative Pembrolizumab Plus Chemo Does Not Significantly Improve EFS in MIBC

  • About
  • Advertise
  • CureToday.com
  • OncLive.com
  • OncNursingNews.com
  • TargetedOnc.com
  • Editorial
  • Contact
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Personal Information
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

Brand Logo

© 2026 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us